Arcadia Investment Management Corp MI Purchases 880 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Arcadia Investment Management Corp MI grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 12.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,815 shares of the biotechnology company’s stock after buying an additional 880 shares during the quarter. Arcadia Investment Management Corp MI’s holdings in Sarepta Therapeutics were worth $499,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Byrne Asset Management LLC acquired a new position in Sarepta Therapeutics in the 1st quarter valued at approximately $30,000. Center for Financial Planning Inc. bought a new stake in shares of Sarepta Therapeutics in the first quarter valued at approximately $31,000. Steward Partners Investment Advisory LLC grew its holdings in Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 194 shares in the last quarter. UMB Bank n.a. increased its holdings in Sarepta Therapeutics by 53.0% during the 1st quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 276 shares during the period. Finally, Smartleaf Asset Management LLC grew its stake in Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock worth $54,000 after buying an additional 216 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Trading Up 9.9%

Shares of Sarepta Therapeutics stock opened at $19.03 on Wednesday. Sarepta Therapeutics, Inc. has a 1 year low of $16.88 and a 1 year high of $154.13. The stock has a fifty day moving average price of $33.62 and a 200-day moving average price of $73.70. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The firm has a market cap of $1.87 billion, a PE ratio of -7.07 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The company had revenue of $744.86 million during the quarter, compared to analysts’ expectations of $685.75 million. During the same quarter in the prior year, the firm posted $0.73 EPS. The firm’s quarterly revenue was up 80.2% on a year-over-year basis. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. BMO Capital Markets cut shares of Sarepta Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $120.00 to $70.00 in a research note on Monday, June 16th. Royal Bank Of Canada reduced their price target on Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating for the company in a report on Wednesday, May 7th. Barclays reduced their price objective on Sarepta Therapeutics from $89.00 to $29.00 and set an “overweight” rating for the company in a report on Tuesday, June 17th. Needham & Company LLC cut their price target on Sarepta Therapeutics from $125.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, June 16th. Finally, Jefferies Financial Group cut their price target on Sarepta Therapeutics from $125.00 to $54.00 and set a “buy” rating for the company in a research note on Monday, June 16th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $60.88.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.